SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 323 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 4.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $636,000 | -14.3% | 19,213 | -9.2% | 0.00% | 0.0% |
| Q1 2019 | $742,000 | +6.6% | 21,162 | +1.0% | 0.00% | 0.0% |
| Q4 2018 | $696,000 | -65.1% | 20,960 | -47.1% | 0.00% | -60.0% |
| Q3 2018 | $1,994,000 | -37.1% | 39,605 | -25.3% | 0.01% | -37.5% |
| Q2 2018 | $3,171,000 | -29.6% | 52,985 | -46.1% | 0.01% | -33.3% |
| Q1 2018 | $4,502,000 | +30.3% | 98,293 | +13.4% | 0.01% | +33.3% |
| Q4 2017 | $3,454,000 | +48.1% | 86,672 | +48.7% | 0.01% | +28.6% |
| Q3 2017 | $2,332,000 | +34.0% | 58,290 | +44.4% | 0.01% | +40.0% |
| Q2 2017 | $1,740,000 | +21.9% | 40,380 | -11.4% | 0.01% | 0.0% |
| Q1 2017 | $1,427,000 | -35.9% | 45,580 | -48.3% | 0.01% | -28.6% |
| Q4 2016 | $2,225,000 | -5.4% | 88,100 | -7.4% | 0.01% | -12.5% |
| Q3 2016 | $2,352,000 | +13.5% | 95,100 | -6.5% | 0.01% | +14.3% |
| Q2 2016 | $2,072,000 | +366.7% | 101,700 | +249.5% | 0.01% | +250.0% |
| Q1 2016 | $444,000 | – | 29,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 7,641,250 | $107,207,000 | 7.06% |
| HealthInvest Partners AB | 782,746 | $10,982,000 | 6.50% |
| KOPP INVESTMENT ADVISORS LLC | 729,960 | $10,241,000 | 5.51% |
| Murphy Michael R | 1,028,304 | $14,427,000 | 4.96% |
| Opaleye Management Inc. | 460,000 | $6,454,000 | 3.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 511,244 | $7,173,000 | 1.68% |
| Bruce & Co., Inc. | 394,581 | $5,535,000 | 1.42% |
| AlphaOne Investment Services, LLC | 235,065 | $3,297,000 | 1.40% |
| Ranger Investment Management | 1,560,453 | $21,893,000 | 1.23% |
| NORTHPOINTE CAPITAL LLC | 584,753 | $8,204,000 | 1.07% |